Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.60
HZNP's Cash to Debt is ranked higher than
60% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. HZNP: 0.60 )
HZNP' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 0.6

Equity to Asset 0.43
HZNP's Equity to Asset is ranked higher than
56% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. HZNP: 0.43 )
HZNP' s 10-Year Equity to Asset Range
Min: -0.77   Max: 0.7
Current: 0.43

-0.77
0.7
F-Score: 4
Z-Score: -0.06
M-Score: 0.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10.41
HZNP's Operating margin (%) is ranked higher than
56% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. HZNP: -10.41 )
HZNP' s 10-Year Operating margin (%) Range
Min: -1841.5   Max: -57.9
Current: -10.41

-1841.5
-57.9
Net-margin (%) -150.03
HZNP's Net-margin (%) is ranked lower than
51% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. HZNP: -150.03 )
HZNP' s 10-Year Net-margin (%) Range
Min: -1632.3   Max: -201.31
Current: -150.03

-1632.3
-201.31
ROE (%) -468.04
HZNP's ROE (%) is ranked lower than
55% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. HZNP: -468.04 )
HZNP' s 10-Year ROE (%) Range
Min: -523.78   Max: -57.66
Current: -468.04

-523.78
-57.66
ROA (%) -77.40
HZNP's ROA (%) is ranked lower than
53% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. HZNP: -77.40 )
HZNP' s 10-Year ROA (%) Range
Min: -176.97   Max: -31.86
Current: -77.4

-176.97
-31.86
ROC (Joel Greenblatt) (%) -584.17
HZNP's ROC (Joel Greenblatt) (%) is ranked higher than
52% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. HZNP: -584.17 )
HZNP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5030.52   Max: -1142.01
Current: -584.17

-5030.52
-1142.01
Revenue Growth (3Y)(%) -14.60
HZNP's Revenue Growth (3Y)(%) is ranked higher than
54% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. HZNP: -14.60 )
HZNP' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -14.6
Current: -14.6

EBITDA Growth (3Y)(%) -74.50
HZNP's EBITDA Growth (3Y)(%) is ranked lower than
52% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. HZNP: -74.50 )
HZNP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -74.5
Current: -74.5

EPS Growth (3Y)(%) -52.00
HZNP's EPS Growth (3Y)(%) is ranked higher than
52% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. HZNP: -52.00 )
HZNP' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -52
Current: -52

» HZNP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

HZNP Guru Trades in Q4 2013

Paul Tudor Jones 14,646 sh (New)
Jim Simons 358,000 sh (New)
» More
Q1 2014

HZNP Guru Trades in Q1 2014

Paul Tudor Jones 16,733 sh (+14.25%)
Jim Simons Sold Out
» More
Q2 2014

HZNP Guru Trades in Q2 2014

Joel Greenblatt 57,769 sh (New)
Paul Tudor Jones Sold Out
» More
Q3 2014

HZNP Guru Trades in Q3 2014

Steven Cohen 934,396 sh (New)
Paul Tudor Jones 294,814 sh (New)
Joel Greenblatt 80,834 sh (+39.93%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 Add 39.93%$8.265 - $16.27 $ 13.4417%80834
Joel Greenblatt 2014-06-30 New Buy0.01%$12.02 - $16.32 $ 13.44-6%57769
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.93
HZNP's P/B is ranked higher than
74% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. HZNP: 2.93 )
HZNP' s 10-Year P/B Range
Min: 0.8   Max: 14.89
Current: 2.93

0.8
14.89
P/S 4.47
HZNP's P/S is ranked higher than
69% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. HZNP: 4.47 )
HZNP' s 10-Year P/S Range
Min: 1.47   Max: 19.46
Current: 4.47

1.47
19.46
PFCF 448.00
HZNP's PFCF is ranked higher than
77% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. HZNP: 448.00 )
HZNP' s 10-Year PFCF Range
Min: 321.33   Max: 448
Current: 448

321.33
448
EV-to-EBIT -75.85
HZNP's EV-to-EBIT is ranked higher than
63% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. HZNP: -75.85 )
HZNP' s 10-Year EV-to-EBIT Range
Min: -84   Max: -0.1
Current: -75.85

-84
-0.1
Current Ratio 1.31
HZNP's Current Ratio is ranked higher than
55% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. HZNP: 1.31 )
HZNP' s 10-Year Current Ratio Range
Min: 0.16   Max: 4.39
Current: 1.31

0.16
4.39
Quick Ratio 1.22
HZNP's Quick Ratio is ranked higher than
62% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. HZNP: 1.22 )
HZNP' s 10-Year Quick Ratio Range
Min: 0.16   Max: 4.27
Current: 1.22

0.16
4.27

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.01
HZNP's Price/Median PS Value is ranked higher than
82% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. HZNP: 1.01 )
HZNP' s 10-Year Price/Median PS Value Range
Min: 0.39   Max: 3.92
Current: 1.01

0.39
3.92
Earnings Yield (Greenblatt) -1.30
HZNP's Earnings Yield (Greenblatt) is ranked higher than
60% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. HZNP: -1.30 )
HZNP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -1.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Horizon Pharma plc to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014 
Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling Shareholder Nov 14 2014 
Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders Nov 13 2014 
Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release Table Nov 12 2014 
Horizon Pharma plc Appoints John J. Kody as Executive Vice President and Chief Commercial Officer Nov 06 2014 
Horizon Pharma plc Announces DUEXIS(R) Selected as Winner of Chicago Innovation Award Oct 31 2014 
Horizon Pharma plc Announces Acquisition of U.S. Rights to PENNSAID(R) 2% From Nuvo Research Inc. Oct 17 2014 
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of A Oct 15 2014 
Horizon Pharma plc Reviews Future ACTIMMUNE(R) Opportunities at Analyst Day Oct 15 2014 
Horizon Pharma plc Receives Orphan-Drug Designation for ACTIMMUNE(R) (Interferon gamma-1b) in Friedr Oct 15 2014 

More From Other Websites
HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... Dec 15 2014
HORIZON PHARMA PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale... Nov 26 2014
Horizon Pharma plc to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014
Horizon Pharma plc to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 24 2014
Horizon Pharma plc Announces Presentation of Data Showing Unmet Need in Rheumatoid Arthritis and the... Nov 18 2014
Horizon Pharma plc Announces Presentation of Data Showing Unmet Need in Rheumatoid Arthritis and the... Nov 18 2014
HORIZON PHARMA PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Nov 14 2014
HORIZON PHARMA PLC Financials Nov 14 2014
Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling... Nov 14 2014
Horizon Pharma plc Announces Pricing of Secondary Offering of Ordinary Shares by Selling... Nov 14 2014
HORIZON PHARMA PLC Files SEC form 8-K, Other Events Nov 13 2014
Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders Nov 13 2014
Horizon Pharma plc Announces Proposed Secondary Offering of Ordinary Shares by Selling Shareholders Nov 13 2014
Horizon Pharma plc Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets and... Nov 12 2014
Horizon Pharma plc Announces Clinical Data on RAYOS(R) (Prednisone) Delayed-Release Tablets and... Nov 12 2014
HORIZON PHARMA PLC Files SEC form 8-K, Other Events Nov 12 2014
Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release... Nov 12 2014
Horizon Pharma plc Announces Favorable Markman Ruling in RAYOS(R) (prednisone) Delayed-Release... Nov 12 2014
Horizon Pharma plc to Present at the Stifel 2014 Healthcare Conference Nov 11 2014
HORIZON PHARMA PLC Files SEC form 8-K, Change in Directors or Principal Officers Nov 10 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK